Passage Bio Total Debt vs. Net Income
| PASG Stock | USD 8.61 0.40 4.44% |
For Passage Bio profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Passage Bio to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Passage Bio utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Passage Bio's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Passage Bio over time as well as its relative position and ranking within its peers.
Check out Your Equity Center. Can Biotechnology industry sustain growth momentum? Does Passage have expansion opportunities? Factors like these will boost the valuation of Passage Bio. Anticipated expansion of Passage directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Passage Bio demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Investors evaluate Passage Bio using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Passage Bio's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. External factors like market trends, sector rotation, and investor psychology can cause Passage Bio's market price to deviate significantly from intrinsic value.
It's important to distinguish between Passage Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Passage Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Passage Bio's market price signifies the transaction level at which participants voluntarily complete trades.
Passage Bio Net Income vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Passage Bio's current stock value. Our valuation model uses many indicators to compare Passage Bio value to that of its competitors to determine the firm's financial worth. Passage Bio is rated top company in total debt category among its peers. It is rated below average in net income category among its peers . At this time, Passage Bio's Net Loss is most likely to decrease significantly in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value Passage Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Passage Total Debt vs. Competition
Passage Bio is rated top company in total debt category among its peers. Total debt of Health Care industry is at this time estimated at about 64.42 Million. Passage Bio totals roughly 25.48 Million in total debt claiming about 40% of equities under Health Care industry.
Passage Net Income vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Passage Bio |
| = | 25.48 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Passage Bio |
| = | (64.77 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Passage Net Income Comparison
Passage Bio is currently under evaluation in net income category among its peers.
Passage Bio Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Passage Bio, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Passage Bio will eventually generate negative long term returns. The profitability progress is the general direction of Passage Bio's change in net profit over the period of time. It can combine multiple indicators of Passage Bio, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 7.2 K | 7.6 K | |
| Net Interest Income | 2.6 M | 2.7 M | |
| Interest Income | 2.6 M | 2.7 M | |
| Operating Income | -63.4 M | -66.5 M | |
| Net Loss | -58.3 M | -61.2 M | |
| Income Before Tax | -58.3 M | -61.2 M | |
| Total Other Income Expense Net | 6.5 M | 6.8 M | |
| Net Loss | -122.5 M | -128.6 M | |
| Net Loss | -58.3 M | -61.2 M | |
| Income Tax Expense | (0.90) | (0.85) | |
| Non Operating Income Net Other | 2 M | 2.1 M | |
| Change To Netincome | 21.8 M | 17.7 M | |
| Net Loss | (24.66) | (25.89) | |
| Income Quality | 0.85 | 0.96 |
Passage Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Passage Bio. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Passage Bio position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Passage Bio's important profitability drivers and their relationship over time.
Passage Bio Earnings Estimation Breakdown
The calculation of Passage Bio's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Passage Bio is estimated to be -2.792 with the future projection ranging from a low of -3.4775 to a high of -0.5875. Please be aware that this consensus of annual earnings estimates for Passage Bio is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-3.48 Lowest | Expected EPS | -0.59 Highest |
Passage Bio Earnings Projection Consensus
Suppose the current estimates of Passage Bio's value are higher than the current market price of the Passage Bio stock. In this case, investors may conclude that Passage Bio is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Passage Bio's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 6 | 34.78% | -2.44 | -2.792 | -14.62 |
Passage Bio Earnings per Share Projection vs Actual
Actual Earning per Share of Passage Bio refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Passage Bio predict the company's earnings will be in the future. The higher the earnings per share of Passage Bio, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Passage Bio Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Passage Bio, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Passage Bio should always be considered in relation to other companies to make a more educated investment decision.Passage Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Passage Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-11-10 | 2025-09-30 | -0.2 | -2.44 | -2.24 | 1120 | ||
2025-08-12 | 2025-06-30 | -0.202 | -2.96 | -2.758 | 1365 | ||
2025-05-12 | 2025-03-31 | -0.2233 | -0.25 | -0.0267 | 11 | ||
2025-03-03 | 2024-12-31 | -0.2 | -0.2 | 0.0 | 0 | ||
2024-11-11 | 2024-09-30 | -0.23 | -0.2355 | -0.0055 | 2 | ||
2024-08-08 | 2024-06-30 | -0.31 | -0.26 | 0.05 | 16 | ||
2024-05-14 | 2024-03-31 | -0.36 | -0.3 | 0.06 | 16 | ||
2024-03-04 | 2023-12-31 | -0.4 | -0.3 | 0.1 | 25 | ||
2023-11-13 | 2023-09-30 | -0.46 | -0.49 | -0.03 | 6 | ||
2023-08-07 | 2023-06-30 | -0.48 | -0.44 | 0.04 | 8 | ||
2023-05-11 | 2023-03-31 | -0.5 | -0.63 | -0.13 | 26 | ||
2023-03-06 | 2022-12-31 | -0.52 | -0.49 | 0.03 | 5 | ||
2022-11-10 | 2022-09-30 | -0.79 | -0.49 | 0.3 | 37 | ||
2022-08-04 | 2022-06-30 | -0.83 | -0.73 | 0.1 | 12 | ||
2022-05-16 | 2022-03-31 | -0.89 | -0.79 | 0.1 | 11 | ||
2022-03-03 | 2021-12-31 | -0.89 | -0.95 | -0.06 | 6 | ||
2021-11-04 | 2021-09-30 | -0.86 | -0.87 | -0.01 | 1 | ||
2021-08-05 | 2021-06-30 | -0.76 | -0.9 | -0.14 | 18 | ||
2021-05-05 | 2021-03-31 | -0.74 | -0.76 | -0.02 | 2 | ||
2021-03-03 | 2020-12-31 | -0.7 | -0.85 | -0.15 | 21 | ||
2020-11-10 | 2020-09-30 | -0.76 | -0.63 | 0.13 | 17 | ||
2020-08-13 | 2020-06-30 | -0.57 | -0.6 | -0.03 | 5 | ||
2020-05-11 | 2020-03-31 | -0.45 | -1.0 | -0.55 | 122 | ||
2020-02-28 | 2019-12-31 | -0.69 | -0.69 | 0.0 | 0 |
Use Passage Bio in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Passage Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Passage Bio will appreciate offsetting losses from the drop in the long position's value.Passage Bio Pair Trading
Passage Bio Pair Trading Analysis
The ability to find closely correlated positions to Passage Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Passage Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Passage Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Passage Bio to buy it.
The correlation of Passage Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Passage Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Passage Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Passage Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Passage Bio position
In addition to having Passage Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Artificial Intelligence Thematic Idea Now
Artificial Intelligence
Technology companies, funds, and ETFs across multiple industries that are involved in research or development in the field of reasoning, learning, natural language processing and perception as well as its application to science and commerce. This theme may also include entities involved in cybernetics and cognitive brain simulation field. The Artificial Intelligence theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Artificial Intelligence Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
To fully project Passage Bio's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Passage Bio at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Passage Bio's income statement, its balance sheet, and the statement of cash flows.